TITLE

WARNING FOR LOPINAVIR/RITONAVIR ORAL SOLUTION

PUB. DATE
April 2011
SOURCE
Contemporary Pediatrics;Apr2011, Vol. 28 Issue 4, p16
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports a warning issued by the US Food and Drug Administration (FDA), as it has estimated severe, possibly fatal, health problems in babies who have received lopinavir/ritonavir oral solution, an antiviral medication used in combination with other antiretroviral drugs to treat HIV-1 infection.
ACCESSION #
60136415

 

Related Articles

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Feb2011, Vol. 25 Issue 2, p123 

    No abstract available.

  • Combination Treatment for HIV.  // Combination Treatment for HIV;4/1/2004, p1 

    The article presents information about combination treatment for human immunodeficiency viruses (HIV). It enumerates the four main types of HIV drugs namely nucleoside analogues, non-nucleoside analogues, protease inhibitors and fusion inhibitors. It cites the side effects of combining these...

  • New risk information added to label of antiviral saquinavir.  // AIDS Alert;Dec2010, Vol. 25 Issue 12, p143 

    The article reports that the U.S. Food and Drug Administration (FDA) is advising the public that another risk information has been included in the label of saquinavir (Invirase®), describing the possible change in the heart's electrical activity when the antiviral drug is administered, along...

  • NDA SUBMITTED FOR AMPRENAVIR.  // AIDS Patient Care & STDs;Jan1999, Vol. 13 Issue 1, p60 

    Reports that a new drug application for the protease inhibitor amprenavir has been submitted to the United States Food and Drug Administration. Antiviral activity of the drug; Preliminary phase III data.

  • Emtriva Receives FDA Nod.  // Guide;Nov2003, Vol. 23 Issue 11, p46 

    Reports on the U.S. Food and Drug Administration's approval of Emtriva for use in combination with other antiretroviral agents in the treatment of HIV infection. Assessment of nucleoside reverse transcriptase inhibitor Emtriva by genotypic or phenotypic testing; Increase in mean baseline CD4...

  • FDA Approves Viread for HIV-1 Infection.  // FDA Consumer;Jan/Feb2002, Vol. 36 Issue 1, p5 

    Reports that the United States Food and Drug Administration has approved Viread, an antiviral drug for the treatment of HIV-1 infection in combination with other antiretroviral medicines. Most frequently reported adverse events among patients in the clinical trials; Marketer of Viread.

  • Prodrug of tenofovir diphosphate approved for combination HIV therapy.  // American Journal of Health-System Pharmacy;1/1/2002, Vol. 59 Issue 1, p18 

    Reports on United States Food and Drug Administration's market approval of tenofovir disopropxil fumarate for the treatment of HIV. Drug effectiveness; Findings of clinical trials; Drug bioavailability; Dosage recommendation; Adverse effects of the drug.

  • Once-a-day triple-drug HIV pill approve.  // Pharmaceutical Technology Europe;Sep2006, Vol. 18 Issue 9, p18 

    The article reports on the approval given to Atripla, a once-a-day triple-drug HIV treatment regimen by the Food and Drug Administration in the U.S. Atripla tablets are a fixed dose combination of three widely used antiretroviral agents that can be used alone or in combination with other...

  • FDA approves four-drug anti-HIV combination tablet. Traynor, Kate // American Journal of Health-System Pharmacy;10/1/2012, Vol. 69 Issue 19, p1616 

    The article reports that the FDA approved a four-drug combination tablet Stribild, marketed by Gilead Sciences Inc. for the use in HIV-infected adults who have not previously undergone treatment for the infection. According to the FDA, the drug is a complete treatment regimen for HIV infection....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics